Your browser doesn't support javascript.
loading
Measurement Assessment of Minimal Disease Activity In Psoriasis in Spain: A National Cross-Sectional Study. / Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional.
Carretero Hernández, G; Ara Martín, M; Armesto Alonso, S; Belinchón Romero, I; Eiris Salvado, N; Ferrán Farrés, M; Galache Osuna, C; García Bustínduy, M; García Latasa de Araníbar, J; Juliá Manresa, M; Llamas Velasco, M; López Ferrer, A; Roncero Riesco, M; Ruiz Genao, D; Ruíz-Villaverde, R; Salgado Boquete, L; Soria Martínez, C; Vilarrasa Rull, E; Descalzo, M A.
Afiliação
  • Carretero Hernández G; Servicio de Dermatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España. Electronic address: gcarreteroh58@gmail.com.
  • Ara Martín M; Servicio de Dermatología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
  • Armesto Alonso S; Servicio de Dermatología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, España.
  • Belinchón Romero I; Servicio de Dermatología, Hospital General Universitario Dr. Balmis-ISABIAL-UMH, Alicante, España.
  • Eiris Salvado N; Servicio de Dermatología, Hospital Universitario Virgen Macarena, Sevilla, España.
  • Ferrán Farrés M; Departamento de Dermatología, Hospital del Mar, Barcelona, España.
  • Galache Osuna C; Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Asturias, España.
  • García Bustínduy M; Servicio de Dermatología, Complejo Hospitalario Universitario de Canarias, La Laguna, Tenerife, España.
  • García Latasa de Araníbar J; Servicio de Dermatología, Hospital Universitario Royo Villanova, Zaragoza, España.
  • Juliá Manresa M; Servicio de Dermatología, Hospital Universitario de Basurto, Bilbao, Vizcaya, España.
  • Llamas Velasco M; Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, España.
  • López Ferrer A; Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
  • Roncero Riesco M; Servicio de Dermatología, Complejo Asistencial Universitario de Salamanca, Salamanca, España.
  • Ruiz Genao D; Servicio de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
  • Ruíz-Villaverde R; Hospital Universitario San Cecilio de Granada, Instituto Biosanitario de Granada, Ibs, Granada, España.
  • Salgado Boquete L; Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, España.
  • Soria Martínez C; Hospital General Universitario Reina Sofía, Murcia, España.
  • Vilarrasa Rull E; Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
  • Descalzo MA; Unidad de Investigación, Fundación Piel Sana AEDV, Madrid, España.
Actas Dermosifiliogr ; 2024 Jun 12.
Article em En, Es | MEDLINE | ID: mdl-38876209
ABSTRACT

INTRODUCTION:

In 2017, the Spanish Academy of Dermatology and Venereology Psoriasis Working Group (PWG) designed the Minimal Disease Activity (MDA) criteria to determine the level of disease activity. We hereby present the results of an observational, cross-sectional, multicenter study of the nationwide application of these criteria. MATERIAL AND

METHODS:

We conducted a non-randomized sampling, stratified to achieve autonomic and provincial representation of consecutive patients with psoriasis (Ps) vulgaris without active arthritis. A total of 830 patients were included 493 men (59.5%), with a mean age of 51.4 years (SD, 14.2), from all autonomous regions of Spain (except for Ceuta and Melilla) and 44 (88%) out of the 50 provinces. A questionnaire was obtained with demographic data, DLQI, subjective assessment-on a scale from 0 to 10-of itching, erythema, desquamation, visibility, and the patients' PASI and BSA.

RESULTS:

More than 50% failed to meet the MDA criteria (491; 59.2%), with significant differences being reported by region, sex, and age. Additionally, significant differences were reported based on the therapy used (P<.001). The use of biological therapies was associated with higher MDA compliance compared to other therapies (59.4% vs 23.3%). No differences were reported among various biological therapies.

CONCLUSIONS:

The overall rate of MDA compliance is low, with differences being based on geographic location, sex, age, and drug used, yet none of these factors separately justify them.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En / Es Revista: Actas Dermosifiliogr Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En / Es Revista: Actas Dermosifiliogr Ano de publicação: 2024 Tipo de documento: Article